Home About us Articles Multimedia Search Instructions Login 
IF 2017: 1.596 (® Clarivate Analytics)
Total Cites: 7606
Q2 in Medicine, General & Internal
Follow Us
Follow Us
  • Users Online: 819
  • Home
  • Print this page
  • Email this page

 Table of Contents  
EDITORIAL
Year : 2018  |  Volume : 131  |  Issue : 16  |  Page : 1891-1893

Bronchiectasis Management in China, What We Can Learn from European Respiratory Society Guidelines


1 Department of Respiratory and Critical Care Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China
2 Department of Respiratory and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Date of Submission25-Jun-2018
Date of Web Publication1-Aug-2018

Correspondence Address:
Prof. Jin-Fu Xu
Department of Respiratory and Critical Care Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433
China
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0366-6999.238134

Rights and Permissions
  Abstract 


Keywords: Bronchiectasis; Challenge; China; Disease Management


How to cite this article:
Wang N, Qu JM, Xu JF. Bronchiectasis Management in China, What We Can Learn from European Respiratory Society Guidelines. Chin Med J 2018;131:1891-3

How to cite this URL:
Wang N, Qu JM, Xu JF. Bronchiectasis Management in China, What We Can Learn from European Respiratory Society Guidelines. Chin Med J [serial online] 2018 [cited 2018 Aug 19];131:1891-3. Available from: http://www.cmj.org/text.asp?2018/131/16/1891/238134




  Introduction Top


Non-cystic fibrosis (CF) bronchiectasis (bronchiectasis) is characterized as permanent airway dilatation, cough, sputum overproduction, and repeat pulmonary infections. It was thought as an orphan disease, and has gained much attention recently. The recent European Respiratory Society (ERS) guidelines for the management of adult bronchiectasis focused on nine key questions,[1] which will shed light on a better management of bronchiectasis. However, despite its fine evidence-based suggestions, there remains some questions when it is being used in China population due to different causes, diseases heterogeneity, geographic distribution, and lacking related studies in China.

The prevalence of bronchiectasis remains unclear. A report from Zhou et al.[2] showed that it was about 1.2% in people more than 40 years old in seven cities of China, which may be severely underestimated. The 2012 Expert Consensus is the only version available for diagnosis and treatment of adult bronchiectasis in China, of which, most suggestions are of low quality of evidences. Here, we summarize three utmost questions with considerations of the situation and the challenges faced in Chinese bronchiectasis patients.


  Pay More Attention to Identifying of Etiological Causes and Comorbidities Top


Standardization of diagnostic criteria can help to elucidate the poor understanding of etiology of bronchiectasis. Given the disease complexity, some comorbidities largely affect its prognostics and disease severity; hence, it is also vital to screen on its comorbidities. The ERS guidelines suggest that differential blood count, serum immunoglobulins (total IgG, IgA, and IgM), could be tested for allergic bronchopulmonary aspergillosis in all adults with a new diagnosis of bronchiectasis. Other tests, such as CF, primary ciliary dyskinesia (PCD), and connective tissue disease could be considered in specific circumstances. While to present understanding of China situation on bronchiectasis, CF and PCD are rare in China. The etiology data of bronchiectasis in Guangzhou and Shandong Provinces both showed that idiopathic, postinfectious (including measles, pertussis, tuberculosis, and childhood or adulthood pneumonia), and immunodeficiency constitute major bronchiectasis etiologies.[3],[4] Notably, more investigation of bronchiectasis is needed to find out the underlying causes in clinical practice, not just simply labeled as idiopathic bronchiectasis.[5],[6] Furthermore, it is worth mentioning that posttuberculosis bronchiectasis takes up a large proportion in our country, which may present poorer lung function, comparing to other varying etiologies. Non-tuberculous mycobacterial lung disease also presents higher percentages than Western countries (nearly 5%); 24 h gastroesophageal pH monitoring would benefit patients with gastroesophageal reflux-related bronchiectasis.[3],[7],[8] Studies have shown that rheumatoid arthritis, chronic obstructive pulmonary disease, asthma, and chronic rhinosinusitis are associated with bronchiectasis.[9],[10],[11],[12] Thus, attention should be paid to these factors to detect bronchiectasis in its initial stages and utilize optimization of patient care in China.


  Optimize the Eradication Antibiotic Treatment in China is Needed Top


Infecting organisms may trigger bronchiectasis exacerbations, which has great impact on patients' disease progression.[6] It is well acknowledged that Pseudomonas aeruginosa is one of the most common pathogens isolated from the sputum or bronchoalveolar lavage fluid and plays an important role in bronchiectasis.[13] Our study reports that P. aeruginos a isolation in patients with non-CF bronchiectasis is a significant prognostic indicator, indicating higher rates of exacerbations.[14] Adults with bronchiectasis with a new isolation of P. aeruginosa are suggested to start eradication antibiotic treatment in ERS guidelines. The ERS eradication treatment suggestions presented as follows [Figure 1]. While eradication antibiotic treatment is not suggested to new isolation of pathogens other than P. aeruginosa. We agree with the principles of eradication of P. aeruginosa in the guidelines; however, more items need to be considered in China. We lack strong evidences for the safety and efficacy of the suggested drugs' doses and durations in China. It is hard to confirm that the therapy course like 3 months is proper or not for Chinese patients due to patients' tolerance and expense issues, regardless of the limitation that inhaled antibiotics have not been approved. Well-designed research is needed to customize proper recommendations for Chinese patients.
Figure 1: ERS eradication treatment suggestions (Quoted from European Respiratory Society guidelines for the management of adult bronchiectasis). ERS: European Respiratory Society.

Click here to view



  Problems Faced in Long-Term Antibiotic Treatment in China Top


Chronic or recurrent pulmonary infections takes an important part in the vicious cycle in bronchiectasis. Long-term antibiotic treatment is suggested for adults with bronchiectasis who have three or more exacerbations per year (conditional recommendation and moderate quality evidence) in the ERS guidelines. Inhaled antibiotics or oral macrolides as well as other specific optional antibiotics could be chosen considering P. aeruginosa infection. We reported that long-term inhaled antibiotic therapy enormously reduced the sputum bacterial density and increased the eradication of sputum P. aeruginosa in non-CF bronchiectasis according to systematic reviewing of the published data.[15] The problem is that there has not any access to inhaled antibiotics in China yet. In addition, the recent results of ciprofloxacin dry powder for inhalation (DPI) are out of expectations for some reasons,[16] while the latest trial of DPI of ciprofloxacin nanoplex shows better ex vivo mucus permeability and antibacterial efficacy [17] and may act as a promising therapy for bronchiectasis. Whether patients with two exacerbations per year but have severer symptoms or marked clinical deterioration should consider long-term antibiotic therapy or not, is also an issue worth debating. To determine the suited patient population, improvements of the inhaler devices and proper formula (twice or thrice daily vs. once daily) in our country perhaps are the next frontier.[18] Furthermore, to elucidate the question that, when administering oral or inhaled antibiotics,[19] which one is more effective in different patients' population, perhaps more data is needed.

As for the choice of macrolides, macrolides are reported to protect against P. aeruginosa infection through inhibition of NLRC4 and NLRP3 inflammasomes, reduce the frequency of exacerbations, and improve the quality of life for its anti-inflammatory, immunomodulatory, and antiviral properties.[20] However, cautions should be given for the associated increase in microbial resistance, bronchospasm as well as risk of cardiovascular death.[21] Thus, while identifying optimal patient population, its pros and cons should be well balanced. Since the relatively higher prevalence of nontuberculosis mycobacteria (NTM) infection in bronchiectasis in China,[7] which is related to worse clinical outcomes and an increased risk of macrolide resistance, active NTM infection should be cautioned before long-term treatment with macrolides. In conclusion, all therapy should be individualized, according to drug accessibility and patients' affordability, as well as a good response to the microbiological environment.


  Prospects Top


After all, while learning from Western countries' experience, implementation of clinical practice guidelines in China is needed, which requires more data from our own country with regard to our specific national conditions and patients' characteristics. Still, many problems remain unsolved, nationwide epidemiological studies to find out the true burden of the bronchiectasis, further investigation of the underlying causes, stable stage management and health education, clinical significance of traditional Chinese medicine in bronchiectasis, and so on.[5],[6],[22] Clearly, further research and larger studies are required to set up strong evidence-based comprehensive managements, to break the vicious cycle, reduce exacerbations, alleviate symptoms, improve quality of life, and decrease the risk of future complications.



 
  References Top

1.
Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, et al. European respiratory society guidelines for the management of adult bronchiectasis. Eur Respir J 2017;50. pii: 1700629. doi: 10.1183/13993003.00629-2017.  Back to cited text no. 1
    
2.
Zhou YM, Wang C, Yao WZ, Chen P, Kang J, Huang SG, et al. The prevalence and risk factors of bronchiectasis in residents aged 40 years old and above in seven cities in China (in Chinese). Chin J Intern Med 2013;52:379-8. doi: 10.3760/cma.j.issn.0578-1426.2013.05.006.  Back to cited text no. 2
    
3.
Guan WJ, Gao YH, Xu G, Lin ZY, Tang Y, Li HM, et al. Aetiology of bronchiectasis in Guangzhou, Southern China. Respirology 2015;20:739-48. doi: 10.1111/resp.12528.  Back to cited text no. 3
    
4.
Qi Q, Wang W, Li T, Zhang Y, Li Y. Aetiology and clinical characteristics of patients with bronchiectasis in a Chinese Han population: A prospective study. Respirology 2015;20:917-24. doi: 10.1111/resp.12574.  Back to cited text no. 4
    
5.
Xu JF, Lin JL, Qu JM. Present situation and challenges of bronchiectasis in China (in Chinese). Chin J Tubere Respir Dis 2017;40:8-10. doi: 10.3760/cma.j.issn.1001-0939.2017.01.003.  Back to cited text no. 5
    
6.
Lin JL, Xu JF, Qu JM. Bronchiectasis in China. Ann Am Thorac Soc 2016;13:609-16. doi: 10.1513/AnnalsATS.201511-740PS.  Back to cited text no. 6
    
7.
Xu JF, Ji XB, Fan LC, Bai JW, Lu HW, Liang S. et al. Clinical analysis of non-tuberculous mycobacterial pulmonary infection in patients with bronchiectasis (in Chinese). Chin J Tuberc Respiratiory Dis 2014;37:301-2. doi: 10.3760/cma.j.issn.1001-0939.2014.04.019.  Back to cited text no. 7
    
8.
Wang H, Ji XB, Li CW, Lu HW, Mao B, Liang S, et al. Clinical characteristics and validation of bronchiectasis severity score systems for post-tuberculosis bronchiectasis. Clin Respir J 2018;23. doi: 10.1111/crj.12911.  Back to cited text no. 8
    
9.
Ding W, Zhao YF, Lu HW, Liang S, Cheng KB, Xu JF, et al. Study on the effect and predictive to bronchiectasis combined with rheumatoid arthritis (in Chinese). Chin J Tubere Respir Dis 2017;40:24-8. doi: 10.3760/cma.j.issn.1001-0939.2017.01.006.  Back to cited text no. 9
    
10.
Mao B, Lu HW, Li MH, Fan LC, Yang JW, Miao XY, et al. The existence of bronchiectasis predicts worse prognosis in patients with COPD. Sci Rep 2015;5:10961. doi: 10.1038/srep10961.  Back to cited text no. 10
    
11.
Mao B, Yang JW, Lu HW, Xu JF. Asthma and bronchiectasis exacerbation. Eur Respir J 2016;47:1680-6. doi: 10.1183/13993003.01862-2015.  Back to cited text no. 11
    
12.
Guan WJ, Gao YH, Li HM, Yuan JJ, Chen RC, Zhong NS, et al. Impacts of co-existing chronic rhinosinusitis on disease severity and risks of exacerbations in Chinese adults with bronchiectasis. PLoS One 2015;10:e0137348. doi: 10.1371/journal.pone.0137348.  Back to cited text no. 12
    
13.
Miao XY, Ji XB, Lu HW, Yang JW, Xu JF. Distribution of major pathogens from sputum and bronchoalveolar lavage fluid in patients with noncystic fibrosis bronchiectasis: A Systematic review. Chin Med J 2015;128:2792-7. doi: 10.4103/0366-6999.167360.  Back to cited text no. 13
[PUBMED]  [Full text]  
14.
Wang H, Ji XB, Mao B, Li CW, Lu HW, Xu JF, et al. Pseudomonas aeruginosa isolation in patients with non-cystic fibrosis bronchiectasis: A retrospective study. BMJ Open 2018;8:e014613. doi: 10.1136/bmjopen-2016-014613.  Back to cited text no. 14
    
15.
Yang JW, Fan LC, Lu HW, Miao XY, Mao B, Xu JF, et al. Efficacy and safety of long-term inhaled antibiotic for patients with noncystic fibrosis bronchiectasis: A meta-analysis. Clin Respir J 2016;10:731-9. doi: 10.1111/crj.12278.  Back to cited text no. 15
    
16.
Aksamit T, Bandel TJ, Criollo M, De Soyza A, Elborn JS, Operschall E, et al. The RESPIRE trials: Two phase III, randomized, multicentre, placebo-controlled trials of ciprofloxacin dry powder for inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis. Contemp Clin Trials 2017;58:78-85. doi: 10.1016/j.cct.2017.05.007.  Back to cited text no. 16
    
17.
Tran TT, Vidaillac C, Yu H, Yong VFL, Roizman D, Chandrasekaran R, et al. Anew therapeutic avenue for bronchiectasis: Dry powder inhaler of ciprofloxacin nanoplex exhibits superior ex vivo mucus permeability and antibacterial efficacy to its native ciprofloxacin counterpart. Int J Pharm 2018;547:368-76. doi: 10.1016/j.ijpharm.2018.06.017.  Back to cited text no. 17
    
18.
Chen CL, Huang Y, Gao YH, Chen RC, Zhong NS, Guan WJ, et al. Inhaled medication therapy for bronchiectasis: Status quo and the next frontier. Expert Opin Investig Drugs 2018;27:211-8. doi: 10.1080/13543784.2018.1439919.  Back to cited text no. 18
    
19.
Spencer S, Felix LM, Milan SJ, Normansell R, Goeminne PC, Chalmers JD, et al. Oral versus inhaled antibiotics for bronchiectasis. Cochrane Database Syst Rev 2018;3:CD012579. doi: 10.1002/14651858.CD012579.pub2.  Back to cited text no. 19
    
20.
Fan LC, Lin JL, Yang JW, Mao B, Lu HW, Ge BX, et al. Macrolides protect against Pseudomonas aeruginosa infection via inhibition of inflammasomes. Am J Physiol Lung Cell Mol Physiol 2017;313:L677-86. doi: 10.1152/ajplung.00123.2017.  Back to cited text no. 20
    
21.
Fan LC, Lu HW, Wei P, Ji XB, Liang S, Xu JF, et al. Effects of long-term use of macrolides in patients with non-cystic fibrosis bronchiectasis: A meta-analysis of randomized controlled trials. BMC Infect Dis 2015;15:160. doi: 10.1186/s12879-015-0872-5.  Back to cited text no. 21
    
22.
Guan WJ, Gao YH, Yuan JJ, Chen RC, Zhong NS. Additional important research priorities for bronchiectasis in China. Eur Respir J 2017;49. pii: 1601747. doi: 10.1183/13993003.01747-2016.  Back to cited text no. 22
    


    Figures

  [Figure 1]



 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
Abstract
Introduction
Pay More Attenti...
Optimize the Era...
Problems Faced i...
Prospects
References
Article Figures

 Article Access Statistics
    Viewed209    
    Printed5    
    Emailed0    
    PDF Downloaded58    
    Comments [Add]    

Recommend this journal




京ICP备05052599号